Optical Mammography in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy

Abstract

Rationale and Objectives We present an optical mammography study that aims to develop quantitative measures of pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Such quantitative measures are based on the concentrations of oxy-hemoglobin ([HbO2]), deoxy-hemoglobin ([Hb]), total hemoglobin ([HbT]), and hemoglobin saturation (SO2) in breast tissue at the tumor location and at sequential time-points during chemotherapy. Materials and Methods Continuous-wave, spectrally resolved optical mammography was performed in transmission and parallel-plate geometry on ten patients prior to treatment initiation and at each NAC administration (mean number of optical mammography sessions: 12; range: 7–18). Data on two patients were discarded for technical reasons. Patients were categorized as responders (>50% decrease in tumor size), or non-responders (<50% decrease in tumor size) based on imaging and histopathology results. Results At 50% completion of the NAC regimen (therapy midpoint), responders (6/8) demonstrated significant decreases in SO2 (−27% ± 4%) and [HbT] (−35 ± 4 µM) at the tumor location with respect to baseline values. By contrast, non-responders (2/8) showed non-significant changes in SO2 and [HbT] at therapy midpoint. We introduce a cumulative response index (CRI) as a quantitative measure of the individual patient’s response to therapy. At therapy midpoint, the SO2-based CRI had a sensitivity of 100% and a specificity of 100% for the identification of responders. Conclusion These results show that optical mammography is a promising tool to assess individual response to NAC at therapy midpoint to guide further decision making for neoadjuvant therapy.

Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment

“…These parameters have been shown to discriminate malignant from healthy tissue in the breast, [18][19][20][21][22][23] and several studies have employed DOSI techniques to explore functional changes in malignancies during NAC and have correlated these changes with response to therapy. 13,[24][25][26][27][28][29][30][31][32][33][34][35] We recently reported the first results of ACRIN-6691, an American College of Radiology Imaging Network (ACRIN) multicenter clinical trial of patients monitored longitudinally by DOSI throughout their NAC regimen. 13 The primary aim of ACRIN-6691 was to evaluate whether a change in a particular DOSI endpoint, the tissue optical index (TOI), could be used to predict a clinical endpoint, pCR, by the midpoint of NAC, ∼2 to 3 months after the first infusion.…”

The Role of Diffuse Optical Spectroscopy in the Diagnosis of Breast Cancer (Case Report)

“…Оптическая диффузионная спектроскопия (ОДС) более 15 лет используется как метод, позволяющий уточнить биологические свойства и прежде всего кислородный статус новообразований молочной железы [10][11][12], а также их изменения под влиянием лечебных воздействий [15][16][17][18][19].…”

Current Methods for the Assessment of Oxygen Status and Biotissue Microcirculation Condition: Diffuse Optical Spectroscopy (Review)

“…The differential diagnosis between malignant and benign breast tumors (content of water, oxy-and deoxyhemoglobin) became one of the main directions of using DOS in oncology [87,88]. In recent years, it was suggested to use variants of DOS to predict individual reaction of neoplasms to therapy and prognosticate treatment efficacy [89][90][91].…”